Skip to main content
. Author manuscript; available in PMC: 2010 Mar 1.
Published in final edited form as: Br J Haematol. 2009 Jan 12;144(6):848–855. doi: 10.1111/j.1365-2141.2008.07548.x

Fig 1.

Fig 1

(a) SGN-40 mediated modest direct cytotoxicity in primary CD19+ CLL cells: CD19+ CLL cells were incubated with 10 µg/mL of indicated antibodies with (W/) or without (W/O) 50µg/mL cross-linking goat anti-human Fc antibody (αFc). The percentage of apoptosis was determined by Annexin V/propidium iodide staining after 24h. (N=8) Annexin V−/PI− cells normalized with the media control are shown as a percentage of live cells.

(b) SGN-40 does not mediate complement-mediated cytotoxicity: CD19+ CLL cells were incubated with 10 µg/mL of SGN-40, rituximab, alemtuzumab or trastuzumab in the presence of 30% of either active or heat-inactivated human serum as a source of complement. Relative cytotoxicity was determined after 1h of incubation at 37°C by Annexin V/propidium iodide staining (N=8)